Get the Stockscreener App
14.19
6.90%
0.9159
Crescent Biopharma Inc stock is traded at $14.19, with a volume of 74,974.
It is up +6.90% in the last 24 hours and up +2,674% over the past month.
See More
Previous Close:
$13.27
Open:
$11.06
24h Volume:
74,974
Relative Volume:
85.00
Market Cap:
$19.42M
Revenue:
$6.67M
Net Income/Loss:
$-47.55M
P/E Ratio:
-9.4573
EPS:
-1.5
Net Cash Flow:
$-17.44M
1W Performance:
+2,674%
1M Performance:
+2,674%
6M Performance:
+2,674%
1Y Performance:
+2,674%
1-Day Range:
$11.06
$15.81
1-Week Range:
$11.06
$19.32
52-Week Range:
$11.06
$19.32
Crescent Biopharma Inc Stock (CBIO) Company Profile
Compare CBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
14.55 | 19.42M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.17 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.51 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.42 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.36 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.88 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
Crisis as catalyst: From Chernobyl evacuation to biotech innovation - BioXconomy
Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks
How To Trade (GYRE) - news.stocktradersdaily.com
Is Costco's BNPL Push a Catalyst for Big-Ticket E-Commerce? - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Hemophilia with Inhibitor Market Statistics Expected - openPR.com
A.I. Drone Operations Flourishing as Global Quantum Computing Market Expected to Reach $5.3 Billion By 2029 - The Globe and Mail
Forge Resources Announces Closing of Further Interest to 80% in Fully Permitted Coal Project, Colombia - The Globe and Mail
Quantum Computing Technology Evolving as Larger Scale of Applications & Uses Skyrockets - The Globe and Mail
AI Analyst Flags Key Risks and Upside for Nvidia Ahead of Earnings - The Globe and Mail
Prediction: SoundHound AI Stock Will Beat the Market. Here's Why. - The Globe and Mail
Zacks Investment Ideas feature highlights: CyberArk, Lam Research and monday.com - The Globe and Mail
(GYRE) Long Term Investment Analysis - news.stocktradersdaily.com
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Factor Investing in Focus: What ETFs Say About Market Direction - The Globe and Mail
Is Navitas Semiconductor Stock a buy After Nvidia Enters the Room? - The Globe and Mail
Where Will Rigetti Computing Be in 3 Years? - The Globe and Mail
Here's How I'd Invest $10,000 Today - The Globe and Mail
How the (GYRE) price action is used to our Advantage - news.stocktradersdaily.com
Barclays Reaffirms Their Hold Rating on Floor & Decor Holdings (FND) - The Globe and Mail
Why JD.com Stock Slumped on Thursday - The Globe and Mail
Will Crimson Data Add Shine To Catalyst Biosciences? - RTTNews
Where are the Opportunities in (GYRE) - news.stocktradersdaily.com
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - BioSpace
Press Release Distribution & PR Platform - ACCESS Newswire
Corteva Invests in Desert Bacteria Startup That Boosted Crop Yields 15% Across 800,000 Acres - Stock Titan
Puna Bio receives investment from Corteva Catalyst - Yahoo Finance
Carnival Is Down 27% in 2025. Is This a Once-in-a-Lifetime Buying Opportunity Before the Stock Goes Parabolic? - The Globe and Mail
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (NASDAQ:DRUG) - Seeking Alpha
AbCellera: Attractively Priced But A Catalyst Is Needed - Seeking Alpha
Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & ConsumablesSpecialty Stocks In Q4 - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Geode Capital Management LLC - Defense World
Wellington Management Group LLP Sells 8,034 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
(GYRE) Proactive Strategies - news.stocktradersdaily.com
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Sei Investments Co. - Defense World
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks
Business - isStories
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win - Investor's Business Daily
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
3 Reasons to Avoid LUMN and 1 Stock to Buy Instead - The Globe and Mail
Hemophilia B Pipeline 2024: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma - Barchart
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
How to Take Advantage of moves in (GYRE) - Stock Traders Daily
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crescent Biopharma Inc Stock (CBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):